A Phase 3, Randomized, Open Label, Controlled Multi Center Study to Evaluate the Safety and Immunogenicity of 4 Doses of MenACWY Conjugate Vaccine, Administered Concomitantly With Routine Vaccines, Among Infants Aged 2 Months.

Trial Profile

A Phase 3, Randomized, Open Label, Controlled Multi Center Study to Evaluate the Safety and Immunogenicity of 4 Doses of MenACWY Conjugate Vaccine, Administered Concomitantly With Routine Vaccines, Among Infants Aged 2 Months.

Completed
Phase of Trial: Phase III

Latest Information Update: 20 May 2014

At a glance

  • Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary)
  • Indications Meningococcal group A infections; Meningococcal group C infections; Meningococcal group W-135 infections; Meningococcal group Y infections; Meningococcal infections
  • Focus Pharmacodynamics
  • Sponsors Novartis Vaccines
  • Most Recent Events

    • 05 Mar 2012 Actual end date (Oct 2011) added as reported by ClinicalTrials.gov.
    • 05 Mar 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 05 Oct 2010 Planned end date changed from 1 Jul 2011 to 1 Dec 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top